536 related articles for article (PubMed ID: 16328345)
1. Elevated levels of serum soluble Fas are associated with organ and tissue damage in systemic lupus erythematosus among Chinese.
Hao JH; Ye DQ; Zhang GQ; Liu HH; Dai H; Huang F; Pan FM; Su H; Dong MX; Chen H; Wang Q; Zhang XJ
Arch Dermatol Res; 2006 Jan; 297(7):329-32. PubMed ID: 16328345
[TBL] [Abstract][Full Text] [Related]
2. Do elevated levels of serum-soluble fas contribute to the persistence of activated lymphocytes in systemic lupus erythematosus?
Bijl M; van Lopik T; Limburg PC; Spronk PE; Jaegers SM; Aarden LA; Smeenk RJ; Kallenberg GG
J Autoimmun; 1998 Oct; 11(5):457-63. PubMed ID: 9802929
[TBL] [Abstract][Full Text] [Related]
3. Relationship of oncogenes (sFas, Bcl-2) and cytokines (IL-10, alfa-TNF) with the activity of systemic lupus erythematosus.
Miret C; Font J; Molina R; Garcia-Carrasco M; Filella X; Ramos M; Cervera R; Ballesta A; Ingelmo M
Anticancer Res; 2001; 21(4B):3053-9. PubMed ID: 11712810
[TBL] [Abstract][Full Text] [Related]
4. Correlation between serum levels of soluble Fas (CD95/Apo-1) with disease activity in systemic lupus erythematosus patients in Khorasan, Iran.
Sahebari M; Hatef MR; Rezaieyazdi Z; Abbasi M; Abbasi B; Mahmoudi M
Arch Iran Med; 2010 Mar; 13(2):135-42. PubMed ID: 20187668
[TBL] [Abstract][Full Text] [Related]
5. Patients with systemic lupus erythematosus with high plasma levels of sFas risk relapse.
van Lopik T; Bijl M; Hart M; Boeije L; Gesner T; Creasy AA; Kallenberg CG; Aarden LA; Smeenk RJ
J Rheumatol; 1999 Jan; 26(1):60-7. PubMed ID: 9918241
[TBL] [Abstract][Full Text] [Related]
6. Serum DNase I, soluble Fas/FasL levels and cell surface Fas expression in patients with SLE: a possible explanation for the lack of efficacy of hrDNase I treatment.
Tinazzi E; Puccetti A; Gerli R; Rigo A; Migliorini P; Simeoni S; Beri R; Dolcino M; Martinelli N; Corrocher R; Lunardi C
Int Immunol; 2009 Mar; 21(3):237-43. PubMed ID: 19181929
[TBL] [Abstract][Full Text] [Related]
7. Serum levels of soluble Fas correlate with indices of organ damage in systemic lupus erythematosus.
Al-Maini MH; Mountz JD; Al-Mohri HA; El-Ageb EM; Al-Riyami BM; Svenson KL; Zhou T; Richens ER
Lupus; 2000; 9(2):132-9. PubMed ID: 10787011
[TBL] [Abstract][Full Text] [Related]
8. Serum soluble Fas levels in patients with autoimmune rheumatic diseases.
Sahin M; Aydintug O; Tunc SE; Tutkak H; Naziroğlu M
Clin Biochem; 2007 Jan; 40(1-2):6-10. PubMed ID: 17056024
[TBL] [Abstract][Full Text] [Related]
9. Elevated levels of soluble fractalkine in active systemic lupus erythematosus: potential involvement in neuropsychiatric manifestations.
Yajima N; Kasama T; Isozaki T; Odai T; Matsunawa M; Negishi M; Ide H; Kameoka Y; Hirohata S; Adachi M
Arthritis Rheum; 2005 Jun; 52(6):1670-5. PubMed ID: 15934075
[TBL] [Abstract][Full Text] [Related]
10. Serum neopterin, tumor necrosis factor-alpha and soluble tumor necrosis factor receptor II (p75) levels and disease activity in Egyptian female patients with systemic lupus erythematosus.
Mahmoud RA; El-Gendi HI; Ahmed HH
Clin Biochem; 2005 Feb; 38(2):134-41. PubMed ID: 15642275
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of nailfold capillaroscopy in systemic lupus erythematosus: correlation with endothelial cell activation markers and disease activity.
Kuryliszyn-Moskal A; Ciolkiewicz M; Klimiuk PA; Sierakowski S
Scand J Rheumatol; 2009; 38(1):38-45. PubMed ID: 18991188
[TBL] [Abstract][Full Text] [Related]
12. Tumor-associated antigens in systemic sclerosis and systemic lupus erythematosus: associations with organ manifestations, immunolaboratory markers and disease activity indices.
Szekanecz E; Szucs G; Szekanecz Z; Tarr T; Antal-Szalmás P; Szamosi S; Szántó J; Kiss E
J Autoimmun; 2008 Dec; 31(4):372-6. PubMed ID: 18926664
[TBL] [Abstract][Full Text] [Related]
13. Serum sFas/sFasL ratio in systemic lupus erythematosus (SLE) is a function of age.
Turi MC; D'Urbano M; Celletti E; Alessandri C; Valesini G; Paganelli R
Arch Gerontol Geriatr; 2009; 49 Suppl 1():221-6. PubMed ID: 19836636
[TBL] [Abstract][Full Text] [Related]
14. Soluble TRAIL concentrations are raised in patients with systemic lupus erythematosus.
Lub-de Hooge MN; de Vries EG; de Jong S; Bijl M
Ann Rheum Dis; 2005 Jun; 64(6):854-8. PubMed ID: 15564310
[TBL] [Abstract][Full Text] [Related]
15. Increased levels of serum protein oxidation and correlation with disease activity in systemic lupus erythematosus.
Morgan PE; Sturgess AD; Davies MJ
Arthritis Rheum; 2005 Jul; 52(7):2069-79. PubMed ID: 15986354
[TBL] [Abstract][Full Text] [Related]
16. Serological levels of apoptotic bodies, sFAS and TNF in lupus erythematosus.
Alecu M; Coman G; Alecu S
Rom J Intern Med; 2000-2001; 38-39():83-8. PubMed ID: 15529575
[TBL] [Abstract][Full Text] [Related]
17. Detection of nucleosome particles in serum and plasma from patients with systemic lupus erythematosus using monoclonal antibody 4H7.
Williams RC; Malone CC; Meyers C; Decker P; Muller S
J Rheumatol; 2001 Jan; 28(1):81-94. PubMed ID: 11196548
[TBL] [Abstract][Full Text] [Related]
18. Levels of soluble Fas/APO-1 in patients with Behçet's disease.
Hamzaoui K; Hamzaoui A; Zakraoui L; Chabbou A
Mediators Inflamm; 1998; 7(2):111-4. PubMed ID: 9836498
[TBL] [Abstract][Full Text] [Related]
19. Homocysteine levels and disease duration independently correlate with coronary artery calcification in patients with systemic lupus erythematosus.
Von Feldt JM; Scalzi LV; Cucchiara AJ; Morthala S; Kealey C; Flagg SD; Genin A; Van Dyke AL; Nackos E; Chander A; Gehrie E; Cron RQ; Whitehead AS
Arthritis Rheum; 2006 Jul; 54(7):2220-7. PubMed ID: 16802358
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of selected endothelial activation markers in patients with systemic lupus erythematosus.
Kuryliszyn-Moskal A; Klimiuk PA; Ciolkiewicz M; Sierakowski S
J Rheumatol; 2008 Jul; 35(7):1307-13. PubMed ID: 18484695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]